Immunohistochemical analysis of diffuse large B-cell lymphoma
Characteristics . | HIV-positive series no. (%) . | HIV-negative series no. (%) . | P2 . |
|---|---|---|---|
| Total patients | 25 | 33 | — |
| Male sex | 21 (84) | 17 (52) | — |
| Median age, y (range) | 40 (31-57) | 49 (20-73) | — |
| Performance status > 1 | 5 (20) | 3 (9) | .26 |
| Stage III or IV | 15 (60) | 25 (76) | .20 |
| LDH greater than normal | 18 (72) | 23 (70) | .85 |
| More than 1 extranodal site | 10 (40) | 12 (36) | .78 |
| High risk age-adjusted International Prognostic Index Score (2 or 3) | 12 (48) | 17 (52) | .79 |
| Immunohistochemical markers* | |||
| MIB-1 ≥80% | 17 (85) | 19 (58) | .04 |
| bcl-2 positive | 3 (16) | 12 (41) | .06 |
| MUM-1 positive | 2 (14) | 7 (22) | .70 |
| CD10 positive | 10 (53) | 5 (19) | .02 |
| bcl-6 positive | 12 (60) | 10 (50) | .53 |
| p53 positive | 14 (64) | 8 (24) | .004 |
Characteristics . | HIV-positive series no. (%) . | HIV-negative series no. (%) . | P2 . |
|---|---|---|---|
| Total patients | 25 | 33 | — |
| Male sex | 21 (84) | 17 (52) | — |
| Median age, y (range) | 40 (31-57) | 49 (20-73) | — |
| Performance status > 1 | 5 (20) | 3 (9) | .26 |
| Stage III or IV | 15 (60) | 25 (76) | .20 |
| LDH greater than normal | 18 (72) | 23 (70) | .85 |
| More than 1 extranodal site | 10 (40) | 12 (36) | .78 |
| High risk age-adjusted International Prognostic Index Score (2 or 3) | 12 (48) | 17 (52) | .79 |
| Immunohistochemical markers* | |||
| MIB-1 ≥80% | 17 (85) | 19 (58) | .04 |
| bcl-2 positive | 3 (16) | 12 (41) | .06 |
| MUM-1 positive | 2 (14) | 7 (22) | .70 |
| CD10 positive | 10 (53) | 5 (19) | .02 |
| bcl-6 positive | 12 (60) | 10 (50) | .53 |
| p53 positive | 14 (64) | 8 (24) | .004 |
— represents not applicable.
Immunohistochemical analysis was performed in all patients with adequate tumor specimens. Due to technical factors or insufficient tissue, all analyses could not be performed in all available specimens.